MediKane - makers of clinically proven dietary management product for diabetes - turns to crowdfunding

- NutriKane D is a safe, concentrated functional food product that has been clinically proven to effectively lower and control blood sugar levels as part of a dietary management regimen for people living with diabetes

- Clinical trials have shown it reduces blood sugar levels by 2.2 times compared to diet and exercise alone

- Alongside NutriKane D, MediKane has multiple gut-health based products made from Australian-grown ingredients in market, all backed by reputable and robust clinical trials in both Australia and the USA

- MediKane is seeking expressions of interest in an equity crowd-sourced funding campaign on the Birchal platform with a goal of raising $1.5 million.

SYDNEY, 8 June 2021: MediKane, an innovative Australian health company, is launching an equity crowd-sourced funding campaign to drive its next stage of growth, with a particular focus on its clinically-proven dietary management product for people living with diabetes, NutriKane D.
 

Led by former FMCG executive Rod Lewis and Dr Malcolm Ball, a well-respected leader in pharmaceutical development, MediKane was launched when the founders saw an opportunity to apply the Food as Medicine philosophy to the treatment of chronic health conditions.
 

MediKane’s flagship product, NutriKane D, is a plant-based functional food product developed using the scientific rigour of the pharmaceutical industry. It has been clinically proven in multiple studies to lower and control blood sugar levels by improving the diversity of the gut microbiome.

Rod Lewis, CEO and co-founder of MediKane, says, “Diabetes is one of the world’s fastest growing chronic conditions, affecting more than 463 million people globally, with another 374 million at risk of Type 2 diabetes. While there are many excellent medications on the market that can help to manage the symptoms, there are no pharmaceutical treatments available that can reverse or cure the condition. We started MediKane with the aim of leveraging the principles of Food as Medicine to develop natural, plant-based products to prevent, manage and reverse chronic conditions; with NutriKane D, we’ve developed a dietary management product that has been clinically proven to lower and control blood sugar levels while also reducing systemic inflammation.”

Results from clinical trials into NutriKane D showed blood sugar levels were reduced by 2.2 times when patients used the product in conjunction with a diet and exercise program, compared to diet and exercise alone. The product also had a notable positive impact on Body Mass Index (BMI) and weight management. Based on these results, the Australian Government provided MediKane with an Australian Research Council (ARC) grant of more than $2 million, which funded a research project led by Distinguished Professor Ian Paulsen of the Department of Molecular Sciences at Macquarie University, who investigated how NutriKane D works in the human body.

“What we found is that NutriKane D greatly increased the diversity of microbes in the gut which is a sign of good gut health,” says Prof Paulsen. “We also saw an increase in bacteria that have anti-inflammatory properties.“

With a growing body of scientific evidence around the importance of gut health and increased interest in the issue globally, MediKane is turning to equity crowd-sourced funding campaign to drive the next stage of growth of the company, including 
strengthening its presence in international markets such as Asia and the USA.

“We know our products work and we have the clinical evidence to prove it, as well as the positive health stories of hundreds of NutriKane customers,” says Lewis. “Our objective is to become a global leader in the development of safe, plant-based health products to help manage specific acute and chronic health problems. The functional food market is growing at an astonishing rate, and we believe MediKane is perfectly positioned to capitalise on the current global focus on Food as Medicine. We invite all Australians to join us as we take our innovative healthcare products to the world. 

MediKane’s equity crowd-sourced funding campaign is currently open for expressions of interest on the Birchal platform at https://www.birchal.com/company/medikane.

NutriKane D is available via selected health food outlets, pharmacies and online at https://nutrikane.com.au.

- ENDS –

Media contact: 

Rachel McDougall

rachel@crystalclearcommunications.com.au

Ph: 0401 694 301

About MediKane

MediKane is a Food as Medicine company that develops Australian-made, natural health products with the scientific rigour of pharmaceutical drug development.

All of MediKane’s products are manufactured in Australia, using Australian-grown ingredients, utilising a multi-step process designed to protect the company’s Intellectual Property and maintain confidentiality of the processing details.

https://www.medikane.com.au

Rod Lewis - CEO and Co-Founder

Rod has had an incredibly diverse career, beginning with qualifications in science (diabetes biochemistry) and management, and working across a range of different industries and fields, from product development, production and construction of manufacturing and distribution facilities, before moving into senior commercial roles.

His professional background includes senior leadership roles at Heinz, Cadbury Schweppes, The Fosters Group, BOC Gases and Legrand.

Dr Malcolm Ball - Chief Scientific Officer and Co-Founder

Over the course of his professional career, Dr Malcolm Ball has designed and obtained regulatory approval for 41 products in the food, medical device, bioanalytical and pharmaceutical areas. He holds a PhD from Macquarie University, where he has also been recognised as a Fellow.

Prior to co-founding MediKane, Dr Ball worked as lead researcher and team leader for a number of technical organisations including the Cooperative Research Centre for Eye Research and Technology, Apollo Life Sciences and Fluorotechnics. He has also consulted on projects for CibaVision, Johnson & Johnson, Macquarie University, Medical Therapeutics Pty Ltd and Novotech Pty Ltd.